All In Biotech

Drug Trial Radar · NCT04821687

A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD

A Randomized, Parallel Group, Multicenter, Prospective, Open-label, Exploratory, Phase 4 Study to Evaluate the Add-on Effect of Opicapone 50 mg or Levodopa 100 mg as First Strategy for the Treatment of Wearing-off in Patients With Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Jun 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 169 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

169

Actual

Start

Jun 17, 2021

Primary completion

Aug 18, 2022

Study completion Aug 18, 2022

Sponsor

Lead sponsor
SK Chemicals Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study to evaluate the add-on efficacy and safety of opicapone 50 mg or an extra dose of L-DOPA 100 mg for the treatment of wearing-off in patients with PD.

Conditions

  • Parkinson Disease

Interventions

  • Ongentys 50mgDrug

    Opicapone 50mg will be added to current and stable therapy of L-DOPA/DDCI

  • Madopar Tab. 125 or Perkin Tab. 25-100mgDrug

    Madopar Tab. 125 or Perkin Tab. 25-100mg will be added to current and stable therapy of L-DOPA/DDCI

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hauser's diaryTime frame: Baseline, at 2 weeks, and 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hallym University Sacred Heart Hospital

    Anyang-si, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.